TrialThe Lancet. Respiratory medicine2021

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.

Tracy J Ruckwardt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.